[Value of an novel molecule, veralipride, in the treatment of menopausal disorders].
Veralipride in a daily dosage of 100 mg given twenty days each month was tested in 17 patients with hot flushes. Hot flushes and attendant psycho-functional symptoms were significantly improved in ten cases. With the exception of drowsiness in a few patients (improved by evening dosing) clinical tolerance was good. No modifications in biologic parameters were recorded. We believe that veralipride should be tried in menopausal psycho-functional disorders whenever hormonal replacement therapy is contraindicated.
D000328:Adult; D002979:Climacteric / Q000187:drug effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011602:Psychophysiologic Disorders / Q000188:drug therapy*; D013469:Sulpiride / Q000031:analogs & derivatives* / Q000627:therapeutic use
D013469:Sulpiride; C027429:veralipride
Intérêt d'une molécule originale, le véralipride, dans le traitement des troubles de la ménopause.